Prognostic Value of Vimentin in Triple Negative Breast Cancer Patients Depends on Chemotherapy Regimen and p53 Mutant Expression

References

• Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. doi:10.1038/35021093
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Jovanovic B, Chen X, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11(6):e0157368. doi:10.1371/journal.pone.0157368
   PubMed Web of Science ®Google Scholar
• Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21(7):1688–1698. doi:10.1158/1078-0432.ccr-14-0432
   PubMed Web of Science ®Google Scholar
• Telli ML, Timms KM, Reid J, et al. Homologous Recombination Deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22(15):3764–3773. doi:10.1158/1078-0432.ccr-15-2477
   PubMed Web of Science ®Google Scholar
• Zhang L, Chen Y, Cheng MY, et al. Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis. Ther Adv Med Oncol. 2022;14:17588359221096253. doi:10.1177/17588359221096253
   Web of Science ®Google Scholar
• Traina TA, Miller K, Yardley DA, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol. 2018;36(9):884–890. doi:10.1200/jco.2016.71.3495
   PubMed Web of Science ®Google Scholar
• Gucalp A, Tolaney S, Isakoff SJ, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res. 2013;19(19):5505–5512. doi:10.1158/1078-0432.ccr-12-3327
   PubMed Web of Science ®Google Scholar
• Bonnefoi H, Grellety T, Tredan O, et al. A phase II trial of Abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann Oncol. 2016;27(5):812–818. doi:10.1093/annonc/mdw067
   PubMed Web of Science ®Google Scholar
• Echavarria I, Lopez-Tarruella S, Picornell A, et al. Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to lehmann’s refined classification. Clin Cancer Res. 2018;24(8):1845–1852. doi:10.1158/1078-0432.ccr-17-1912
   PubMed Web of Science ®Google Scholar
• Yamashita N, Tokunaga E, Kitao H, et al. Vimentin as a poor prognostic factor for triple-negative breast cancer. J Cancer Res Clin Oncol. 2013;139(5):739–746. doi:10.1007/s00432-013-1376-6
   PubMed Web of Science ®Google Scholar
• Khillare CD, Sinai Khandeparkar SG, Joshi AR, et al. Immunohistochemical expression of vimentin in invasive breast carcinoma and its correlation with clinicopathological parameters. Niger Med J. 2019;60(1):17–21. doi:10.4103/nmj.nmj_7_19
   PubMedGoogle Scholar
• Usman S, Waseem NH, Nguyen TKN, et al. Vimentin is at the heart of epithelial mesenchymal transition (EMT) mediated metastasis. Cancers. 2021;13(19):4985. doi:10.3390/cancers13194985
   PubMed Web of Science ®Google Scholar
• Dine JL, O’Sullivan CC, Voeller D, et al. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. Breast Cancer Res Treat. 2016;155(2):235–251. doi:10.1007/s10549-015-3673-z
   PubMed Web of Science ®Google Scholar
• Schmidt G, Solomayer EF, Bohle RM, et al. Is vimentin a potential prognostic factor for patients with triple-negative breast cancer? J Cancer Res Clin Oncol. 2020;146(8):2109–2116. doi:10.1007/s00432-020-03210-0
   PubMed Web of Science ®Google Scholar
• Kusinska RU, Kordek R, Pluciennik E, et al. Does vimentin help to delineate the so-called ‘basal type breast cancer’? J Exp Clin Cancer Res. 2009;28(1):118. doi:10.1186/1756-9966-28-118
   PubMedGoogle Scholar
• Dhar G, Banerjee S, Dhar K, et al. Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2. Cancer Res. 2008;68(12):4580–4587. doi:10.1158/0008-5472.can-08-0316
   PubMed Web of Science ®Google Scholar
• Coradini D, Fornili M, Ambrogi F, et al. TP53 mutation, epithelial-mesenchymal transition, and stem like features in breast cancer subtypes. J Biomed Biotechnol. 2012;2012:254085. doi:10.1155/2012/254085
   PubMedGoogle Scholar
• Yaourtis AM, Levina A, Lay PA. Tumour cell heterogeneity in triple-negative breast cancer cells affects response to cisplatin, but not doxorubicin. J Inorg Biochem. 2022;239:112082. doi:10.1016/j.jinorgbio.2022.112082
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–2767. doi:10.1172/jci45014
   PubMed Web of Science ®Google Scholar
• Hill DP, Harper A, Malcolm J, et al. Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance. BMC Cancer. 2019;19(1):1039. doi:10.1186/s12885-019-6278-9
   PubMed Web of Science ®Google Scholar
• Silwal-Pandit L, Vollan HK, Chin SF, et al. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clin Cancer Res. 2014;20(13):3569–3580. doi:10.1158/1078-0432.ccr-13-2943
   PubMed Web of Science ®Google Scholar
• Nik-Zainal S, Davies H, Staaf J, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534(7605):47–54. doi:10.1038/nature17676
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. doi:10.1038/nature11412
   PubMed Web of Science ®Google Scholar
• Shahbandi A, Nguyen HD, Jackson JG. TP53 mutations and outcomes in breast cancer: reading beyond the headlines. Trends Cancer. 2020;6(2):98–110. doi:10.1016/j.trecan.2020.01.007
   PubMed Web of Science ®Google Scholar
• Pogoda K, Niwinska A, Murawska M, Pienkowski T. Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol. 2013;30(1):388. doi:10.1007/s12032-012-0388-4
   PubMed Web of Science ®Google Scholar
• Yuan N, Meng M, Liu C, et al. Clinical characteristics and prognostic analysis of triple-negative breast cancer patients. Mol Clin Oncol. 2014;2(2):245–251. doi:10.3892/mco.2013.230
   PubMedGoogle Scholar
• Tseng LM, Hsu NC, Chen SC, et al. Distant metastasis in triple-negative breast cancer. Neoplasma. 2013;60(3):290–294. doi:10.4149/neo_2013_038
   PubMed Web of Science ®Google Scholar
• Ma KK, Chau WW, Wong CH, et al. Triple negative status is a poor prognostic indicator in Chinese women with breast cancer: a ten year review. Asian Pac J Cancer Prev. 2012;13(5):2109–2114. doi:10.7314/apjcp.2012.13.5.2109
   PubMedGoogle Scholar
• Mousavi SA, Kasaeian A, Pourkasmaee M, et al. Assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in Iran. PLoS One. 2019;14(1):e0208701.
   PubMed Web of Science ®Google Scholar
• Wahidin M, Febrianti R, Susanty F, Hasanah SR. Twelve years implementation of cervical and breast cancer screening program in Indonesia. Asian Pac J Cancer Prev. 2022;23(3):829–837. doi:10.31557/apjcp.2022.23.3.829
   PubMedGoogle Scholar